The efficacy and safety of combined EGFR inhibitors and RT has also been confirmed in patients with ESCC who are intolerant of CCRT.18,19 The pilot study of erlotinib plus RT revealed a 2-year survival rate of 44.4% with a reasonable safety profile.18 The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.